drugset / Trial / NCT05363605
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This first-in-human study evaluates safety, tolerability and distribution of \[225Ac\] FPI-1966, \[111In\]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
Timeline
- Start
- 2022-04-20
- Primary completion
- 2023-09-08
- Completion
- 2023-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vofatamab | Monoclonal antibody | — | — |
| Subject | [111In]-FPI-1967 | Diagnostic / imaging agent | 185 mbq | — |
| Subject | [225Ac]-FPI-1966 | Other / unclassified | — | — |